Dr Jean-Claude Forest is a clinical researcher, member of the Research Center of the CHU de Québec-Université Laval, Professor of Laboratory Medicine at the Laval University School of Medicine and Member of the Department of Laboratory Medicine of the CHU de Québec. From 2004 to 2011, he has been the Director of the Research Center of the University Hospital and Associate General Director for Medical and University Affairs from 2010 to 2017. His main research interests are the development of biological markers for the screening and diagnostic of fetal anomalies and diseases associated with pregnancy, such as preeclampsia and gestational diabetes. He is the author or co-author of more than 600 papers, book chapters, scientific communications as well as a speaker at several events. His work has been instrumental in the development of prenatal screening procedures for trisomy 21. He happens to be the Chair of the Coordinating Committee of the Quebec Prenatal Screening Program for Trisomy 21, for which he has played a major role in the implementation. From 1994 to 2006, he has been successively Member, Vice-Chair and Chair of the Scientific Division of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). From 2006 to 2009, he chaired the Joint Committee on Metrological Traceability and, from 2005 to 2010, he was Delegate to the Expert Panel of WHO on Biological Standardization. He received numerous national and international awards and distinctions. For instance, in 2017, he was awarded one of the highest distinctions of the Canadian Medical Association, the Medal of Service, and from the IFCC, the IFCC-Abbott Visiting Lecturer Award.
10, rue de l'Espinay
Canada G1L 3L5
Canadian SARS-CoV-2 serological survey using antenatal serum samples: a retrospective seroprevalence studyJournal Article
CMAJ Open, 11 (2), 2023.
First-trimester screening for Down syndrome using quadruple maternal biochemical markersJournal Article
Clin Chem Lab Med, 61 (9), 2023.
User Experience of a Computer-Based Decision Aid for Prenatal Trisomy Screening: Mixed Methods Explanatory StudyJournal Article
JMIR Pediatr Parent, 5 (3), 2022.
External validation of prognostic models to predict stillbirth using International Prediction of Pregnancy Complications (IPPIC) Network database: individual participant data meta-analysisJournal Article
Ultrasound Obstet Gynecol, 59 (2), 2022.
Sex-specific association of high maternal psychological stress during pregnancy on newborn birthweightJournal Article
PLoS One, 17 (1), 2022.
Proteomic Analysis of Maternal Urine for the Early Detection of Preeclampsia and Fetal Growth RestrictionJournal Article
J Clin Med, 10 (20), 2021.
Frequency, timing and risk factors for primary maternal cytomegalovirus infection during pregnancy in QuebecJournal Article
PLoS One, 16 (6), 2021.
External validation of prognostic models predicting pre-eclampsia: individual participant data meta-analysisJournal Article
BMC Med, 18 (1), 2020.
Study of sRAGE, HMGB1, AGE, and S100A8/A9 Concentrations in Plasma and in Serum-Extracted Extracellular Vesicles of Pregnant Women With Preterm Premature Rupture of MembranesJournal Article
Front Physiol, 11 , 2020.
Cord blood S100B: reference ranges and interest for early identification of newborns with brain injuryJournal Article
Clin Chem Lab Med, 58 (2), 2020.
- Analytical mobile application to support shared decision making for pregnant women, from 2017-09-01 to 2024-03-31
- Maternal serum Brain-Derived Neurotrophic Factor (BDNF): Study of a promising biomarker of maternal psychological stress during pregnancy, from 2022-04-01 to 2023-09-30
- PEGASUS-2 - PErsonalized Genomics for prenatal Abnormalities Screening USing maternal blood : Towards First Tier Screening and Beyond, from 2018-04-01 to 2024-03-31
- Protocole FITRAPS : Analyse de la stabilité des biomarqueurs placentaires, from 2023-09-01 to 2023-11-13
Recently finished projects
- Canadian Population Serological Survey Utilizing Antenatal Serum Samples, from 2021-07-20 to 2022-03-31
- COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal, from 2021-12-01 to 2022-11-30